Summary
Mr. Market has looked beyond Gilead's two huge product line successes and wants fresh successes from the pipeline.
Gilead has indeed been playing catch-up and now has numerous R&D programs underway.
This article discusses most of the company's pipeline; i.e. "all the rest" aside from HCV and HIV/AIDS, and antibody GS-5745 recently discussed.
The general conclusion is that there are promising areas, but nothing definitive.
For now, the major reason to hold the shares comes from the HCV and HIV/AIDS product lines; I continue to find very good relative value in GILD.
Introduction
In between watching and participating in all the market action last week, I made time to do some deep dives into Gilead's (NASDAQ:GILD) pipeline. This analysis was of the listed pipeline candidates that do not have to do with hepatitis C treatment or HIV/AIDS treatments. Also, I recently covered its antibody GS-5745, which is in trials for a variety of malignant and inflammatory diseases.
Because so much of the remaining pipeline is uncertain and mid-stage or earlier, or has been discussed before by me and other writers, I have decided to summarize my findings into one article. It's perhaps a bit long, but being comprehensive may make it easier for readers interested in using this as a reference as results from the clinical trials come in.
Overall, GILD's R&D and related business development performance has been simply phenomenal. Only Regeneron (NASDAQ:REGN), which is in an earlier stage of product development but was formed right around the same year as GILD, may be its equal over time; and Celgene (NASDAQ:CELG) may come close.
However, Mr. Market does not have to care about past performance. He thinks that all GILD has proven is that it can dominate anti-viral product development, but that's a limited field.
Right now he's worried about GILD's future, and as this review shows, he's not being unreasonable.
This article will first run through GILD's list of pipeline candidates in the rough order in which they appear on its website. Where appropriate, some links to related information will be provided. A fair amount of background will be provided, but to make this all fit into one article and to avoid being overly technical, I'll try to keep things focused so that generalists can fully understand each section. Readers are invited to add their own links or cut-and-pastes in the comments section to enhance the quality of the article.
Mr. Market has looked beyond Gilead's two huge product line successes and wants fresh successes from the pipeline.
Gilead has indeed been playing catch-up and now has numerous R&D programs underway.
This article discusses most of the company's pipeline; i.e. "all the rest" aside from HCV and HIV/AIDS, and antibody GS-5745 recently discussed.
The general conclusion is that there are promising areas, but nothing definitive.
For now, the major reason to hold the shares comes from the HCV and HIV/AIDS product lines; I continue to find very good relative value in GILD.
Introduction
In between watching and participating in all the market action last week, I made time to do some deep dives into Gilead's (NASDAQ:GILD) pipeline. This analysis was of the listed pipeline candidates that do not have to do with hepatitis C treatment or HIV/AIDS treatments. Also, I recently covered its antibody GS-5745, which is in trials for a variety of malignant and inflammatory diseases.
Because so much of the remaining pipeline is uncertain and mid-stage or earlier, or has been discussed before by me and other writers, I have decided to summarize my findings into one article. It's perhaps a bit long, but being comprehensive may make it easier for readers interested in using this as a reference as results from the clinical trials come in.
Overall, GILD's R&D and related business development performance has been simply phenomenal. Only Regeneron (NASDAQ:REGN), which is in an earlier stage of product development but was formed right around the same year as GILD, may be its equal over time; and Celgene (NASDAQ:CELG) may come close.
However, Mr. Market does not have to care about past performance. He thinks that all GILD has proven is that it can dominate anti-viral product development, but that's a limited field.
Right now he's worried about GILD's future, and as this review shows, he's not being unreasonable.
This article will first run through GILD's list of pipeline candidates in the rough order in which they appear on its website. Where appropriate, some links to related information will be provided. A fair amount of background will be provided, but to make this all fit into one article and to avoid being overly technical, I'll try to keep things focused so that generalists can fully understand each section. Readers are invited to add their own links or cut-and-pastes in the comments section to enhance the quality of the article.
No comments:
Post a Comment